Achaogen Awarded $24.7M Biodefense Contract by DTRA

- Four-year contract funds preclinical development of therapies to combat anthrax, plague -

SOUTH SAN FRANCISCO, CA — Achaogen, Inc., a developer of novel antibacterial compounds, has executed a four-year contract with the Defense Threat Reduction Agency (DTRA), an agency of the United States Department of Defense, worth up to $24.7 million dollars for the development of therapies to treat anthrax and other biothreat agents.

Under the terms of the agreement, the first year of which is fully funded, DTRA will fund the discovery of "achaogens," novel broad-spectrum small molecule therapeutics that inhibit proprietary bacterial targets, to treat resistant strains of biothreat agents such as B. anthracis (anthrax) or Y. pestis (plague), making the bacteria susceptible to existing fluoroquinolones and potentially to other classes of antibacterial drugs.  Achaogen will then pursue subsequent preclinical development activities culminating in an IND filing with the FDA.

"We are excited and proud that DTRA has partnered with Achaogen," said J. Kevin Judice, Achaogen's CSO. "We will build upon our successful proof of concept with the Defense Advanced Research Projects Agency (DARPA), in which we showed that
"achaogens" can sensitize resistant strains of anthrax, making them susceptible to existing fluoroquinolones, while inhibiting the emergence of new types of resistance."

"The DTRA contract provides funding for our preclinical development efforts into the biodefense arena, while preserving and enhancing our opportunity in the civilian market for the treatment of resistant bacteria," said John Hollway, Achaogen's Vice President of Business Development. "Developing therapies in parallel for both biodefense and hospital-acquired resistant infections will move both programs forward more efficiently and cost-effectively."

ABOUT ACHAOGEN, INC.:
Achaogen (a-KAY-oh-jen) specializes in the discovery and development of small molecules to treat infections caused by bacteria, and by antibiotic-resistant strains in particular.  Achaogen focuses on high value bacterial targets that are validated, but not yet addressed by safe and effective drugs. Achaogen's programs include its SOS-pathway program, focused on the inhibition of bacterial resistance in combination with fluoroquinolones and other drug classes; its aminoglycoside program, focused on the development of compounds that address aminoglycoside-resistant Gram-negative pathogens; and an internal program focused on hospital-acquired Gram-positive and Gram-negative pathogens. For more information about Achaogen please contact John Hollway, Vice President, Business Development at 650-266-1131 or bd@achaogen.com, or visit www.achaogen.com.

Achaogen Closes Series B Financing

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Achaogen, Inc., a developer of novel antibacterial compounds, announced today that it has closed its Series B round of financing, raising over $26 million dollars in a round led by new investor Domain Venture Partners. All of Achaogen's Series A investors (5AM Ventures, ARCH Venture Partners, Venrock Associates, and Versant Ventures) also participated in the Series B round. The company will use the money to advance its lead antibacterial program through clinical proof of concept, and to progress additional programs through preclinical development. 

"Achaogen has made substantial progress as a company since our start in late 2004," said J. Kevin Judice, Achaogen's CSO. "We have shown that our focus on small molecules that inhibit the emergence of bacterial resistance has a broad market with a clean regulatory path forward, and will present the company with a myriad of compelling strategic opportunities in the future. In addition, our aminoglycoside program is advancing rapidly through preclinical development, and we have initiated a third antibacterial program with broad-spectrum potential. We are pleased to welcome Domain Venture Partners to our world-class syndicate of life science investors as we begin the next phase of Achaogen's growth." 

Bob More of Domain will join Achaogen's board of directors. "I am excited to invest in Achaogen and join its board," said Mr. More. "Achaogen's science is an ingenious approach to the serious problem of bacterial resistance to antibiotics, and we see great potential for the company's growth in the underserved antibacterial marketplace." 

ABOUT ACHAOGEN, INC.:
Achaogen specializes in the discovery and development of small molecules to treat infections caused by bacterial infection, and by antibiotic-resistant strains in particular. Achaogen focuses on high value bacterial targets that are validated, but not yet addressed by safe and effective drugs. Achaogen's programs include its SOS-pathway program, focused on the inhibition of bacterial resistance in combination with fluoroquinolones and other drug classes; its aminoglycoside program, focused on the development of compounds that address aminoglycoside-resistant Gram-negative pathogens; and an internal program focused on hospital-acquired Gram-positive and Gram-negative pathogens. For more information about Achaogen please contact John Hollway, Vice President, Business Development at 650-266-1131 or visit www.achaogen.com.